BusinessEpizyme’s chief executive is taking aim at disease that threatened his life By Robert Weisman — Boston GlobeDec. 5, 2015 Reprints Paul A. Volberding Epizyme’s chief executive is taking aim at a disease that threatened his life About the Author Reprints Robert Weisman — Boston Globe [email protected] @GlobeRobW
Biotech Bob Herman and Damian Garde STAT Plus: Moderna CEO made $398 million in 2022, but still pledges to give most to charity
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
A STAT Investigation Casey Ross and Bob Herman STAT Plus: Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need
Special Report Jason Mast, Allison DeAngelis and Megan Molteni STAT Plus: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools